3 Page 3 of 5 Research Project: Organophosphate Pesticide Exposure and Reproductive Toxicity HSPH Project Number: 9605ORGA In its July 24, 2002 letter, OHRP expressed the following unresolved concerns and questions: (1) OHRP expressed concern about an abstract published by Dr. Xu and others at the American Society of Human Genetics 48 th Annual Meeting, October 27-31, 1998, entitled A novel and large-scale population genetics study of human phenotypic variation. OHRP acknowledges HSPH s statement that the language in the abstract was vaguely written and conducive to confusion and that the research was not conducted. (2) OHRP expressed concern that HSPH did not appear to have written IRB policies and procedures that adequately describe the following activities, as required by HHS regulations at 45 CFR (a) and (b)(5): the procedures for ensuring prompt reporting to OHRP of any unanticipated problems involving risks to subjects or others or any serious or continuing noncompliance with 45 CFR part 46 or the requirements or determinations of the IRB. OHRP acknowledges that the HSPH written IRB procedures now clearly address these activities. OHRP finds that this corrective action adequately addresses the above concern and is appropriate under the HSPH FWA. (3) OHRP expressed concern that the informed consent document for the study Organophosphate pesticide exposure and reproductive toxicity may have failed to include information about genetic testing of subjects blood. HSPH acknowledged that the informed consent document for this study did not include these procedures, and that the study has not been renewed. OHRP acknowledges that HSPH has been planning, in cooperation with colleagues in China, to conduct real-time consent monitoring of the two projects that Dr. Xu plans to resume when OHRP s investigation is complete. In addition, HSPH has established a standing oversight committee to guide Dr. Xu s work at HSPH. The HSPH IRB also now pays closer attention to comparing the procedures listed on the protocol applications with those described in the consent document, and the IRB stresses to investigators in its training module that informed consent documents must include all procedures affecting human participants. OHRP finds that these corrective actions adequately address the above concern and are appropriate under the HSPH FWA. (4) OHRP noted that the HSPH IRB found, upon initial review, that the project # R01 HL64109 Genetics of Hypertension and its Intermediate Phenotypes involved no more than minimal risk. HHS regulations at 45 CFR (i) define minimal risk as meaning that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. OHRP expressed concern that some of

4 Page 4 of 5 the interventions in the protocol exceeded the level of minimal risk as defined by the regulations. OHRP acknowledges that the HSPH IRB has reassessed the risk level of this protocol and determined that the risk levels of these procedures are more than minimal but not likely to exceed moderate risk. OHRP finds that this response adequately addresses the above concern and is appropriate under the HSPH FWA. OHRP also acknowledges that Dr. Xu has decided not to continue the hypertension study. (5) OHRP acknowledges that additional concerns and allegations regarding research conducted by Dr. Xu in China contained in a June 3, 2002 letter from the complainant have been investigated by an external auditor and that corrective actions are being implemented by HSPH to address the findings of the external auditor. OHRP notes that these findings are largely similar to findings that OHRP had previously made regarding other studies. OHRP finds that the corrective actions already taken and those described in the audit report adequately address these findings and are appropriate under the HSPH FWA. (6) OHRP received a letter on June 19, 2002 regarding additional concerns and allegations from an anonymous complainant in China. The letter alleged that Dr. Xu directed Chinese researchers and employees to forge informed consent documents for several studies. OHRP requested that HSPH investigate this serious allegation and report to OHRP its findings regarding the possible forging and back-dating of informed consent documents. OHRP acknowledges that HSPH has extensively investigated these allegations and can find no evidence to substantiate the allegations. As a result, OHRP finds that the allegations of forged informed consent documents cannot be substantiated. As a result of the above determinations, there should be no need for further involvement of OHRP in this matter. Of course, OHRP must be notified should new information be identified which might alter this determination. OHRP appreciates the continued commitment of your institution to the protection of human research subjects. Please do not hesitate to contact me should you have any questions. Sincerely, Kristina C. Borror, Ph.D. Compliance Oversight Coordinator Division of Compliance Oversight cc: Ms. Sarah Putney, HSPH Dr. Troyen A. Brennan, Chair, IRB, HSPH

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Donald E. Wilson, M.D., M.A. Dean, School of Medicine University of Maryland Baltimore Professional Schools

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Karena.Cooper@hhs.gov Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite

DEPARTMENT OF HEALTH & HUMAN SERVICES Office of the Secretary Office of Public Health and Science Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1100 Wootton Parkway, Suite 200 Rockville, Maryland

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1100 Wootton Parkway, Suite 200 Rockville, Maryland

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science John M. Allen Assistant Vice President for Scientific Affairs Office of Scientific Affairs and Biotechnology

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Robert M. Mahley, M.D., Ph.D. President The J. David Gladstone Institutes P.O. Box 419100 San Francisco,

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland

Department of Defense Human Research Protection Program AIR FORCE ISSUED DEPARTMENT OF DEFENSE (DOD) INDIVIDUAL INVESTIGATOR AGREEMENT 3/3/2009 General Instructions to Institutions and Unaffiliated Investigators

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers Introduction The purpose of this module is to provide a basic understanding of the responsibilities of the principal

Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland

2014 Metrics on Human Research Protection Program Performance Updated May 15, 2015 About the Metrics Improving the quality of human research protection programs (HRPP) is a top priority of AAHRPP. Effective

Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues This guidance represents

Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT Regulatory changes will occur for investigators studying human DNA The recent acceleration and widening

University of New England Institutional Review Board (IRB) Student Classroom Projects Involving Human Subjects (Guidance for Faculty) The University of New England (UNE) supports a wide range of both undergraduate

Reporting of Adverse Events and Unanticipated Problems Policy date: 12/2011 Purpose The purpose of this policy is to ensure that the review, reporting and analysis of adverse events and unanticipated problems

Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal

MEREDITH COLLEGE INSTITUTIONAL REVIEW BOARD GUIDELINES FOR THE PROTECTION OF HUMAN PARTICIPANTS IN RESEARCH I. Introduction Recognizing its responsibility to provide measures to reasonably protect individuals

Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM DoD/DON-funded Research Policy In 2006, the Department of the Navy (DON) enhanced its human subject protection requirements, including

1 Serving the public and non-profit sectors through independent program evaluation, applied research, and technical assistance. EVALUATION BRIEF Understanding the Institutional Review Board (IRB) January

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION

[This letter reflects the removal of an addressee that was not engaged in this human subjects research and replaces the previously issued determination letter (dated February 8, 2013).] Office of the Secretary

Appendix IV HIPAA Compliance and IRB Approval for the NOPR HIPAA Compliance and Participation in the NOPR The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires that providers

Connecticut Pipe Trades Health Fund Privacy Notice 2013 Restatement Section 1: Purpose of This Notice and Effective Date THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED

To IRB, or Not to IRB? That Is the Question! A presentation by Mary Sapp, Ph.D. Assistant Vice President, Planning & Institutional Research University of Miami and Thomas K. Martin, Ph.D. Associate Vice

Page 1 of 152 Institutional Review Board for Protection of Human Subjects Policies and Procedures Manual for Faculty, Staff, and Student Researchers Office of Research and Economic Development University

PROTOCOL DEVIATIONS 229 1 of 7 PURPOSE The purpose of this policy is to define protocol deviations and the subsequent actions required by the Principal Investigator (PI) once a protocol deviation occurs

Post-Approval Compliance Monitoring: A Responsibility of the Human Research Protection Program (but how to do it?) Monika S. Markowitz, PhD Director, Office of Education and Compliance Oversight Office

Considerations for Waivers of Informed Consent and Authorization Contents: Waiver of Informed Consent... 1 Office for Human Research Protections (OHRP) regulations... 1 Government projects... 1 All other

USE OF HUMAN SUBJECTS IN RESEARCH PRESENTED BY BRIAN WEIMER TULANE UNIVERSITY RESEARCH COMPLIANCE OFFICER June 14, 2011 Objectives of Presentation What is the role of the Research Compliance Officer? Why

911 Data Center Operations Performance Audit June 2010 Office of the Auditor Audit Services Division City and County of Denver Dennis J. Gallagher Auditor The Auditor of the City and County of Denver is

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

The Centers for Disease Control and Prevention (CDC 1 ) has issued the Human Research Protections Policy 1. Reason for Issue: This policy is CDC s first policy on Human Research Protections and it affirms

Evaluation Instrument for Accreditation January 1, 2015 Copyright 2002-2014 AAHRPP. All rights reserved. Use of the Evaluation Instrument for Accreditation The Evaluation Instrument for Accreditation is

Internal Audit Department November 2015 Report Number FY 16-03 This page left blank intentionally. November 30, 2015 Summary Our audit of NAU s is in the Annual Audit Plan for FY 2016, as approved by the

Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

Gulf War and Health: Update of Health Effects of Serving in the Gulf War Statement of Stephen L. Hauser, M.D. Professor and Chair of Neurology University of California, San Francisco, School of Medicine

703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a